Drug Trial Radar · NCT00150579
Efficacy and Safety of SPD465 in Adults With ADHD
Last checked: Nov 19, 2026Latest source record: Jun 30, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
240
Actual
Start
Jan 27, 2005
Primary completion
Jun 14, 2005
Study completion Jun 14, 2005
Sponsor
- Lead sponsor
- ShireTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Sep 8, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety and effectiveness of SPD465 compared to placebo (a capsule with no medication in it) in the treatment of ADHD. The study will also look at how SPD465 affects sleep and how the participants perceive their quality of life.
Conditions
- Attention Deficit Disorder With Hyperactivity
Interventions
Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrateDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in the ADHD-rating scale 4th Edition (ADHD-RS-IV) total score to the Endpoint assessment.Time frame: Baseline, and the Endpoint (average of weeks 5, 6, 7).
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.